Metabolomic changes after DAAs therapy are related to the improvement of cirrhosis and inflammation in HIV/HCV-coinfected patients

被引:7
|
作者
Virseda-Berdices, Ana [1 ,2 ]
Rojo, David [3 ]
Martinez, Isidoro [1 ,2 ]
Berenguer, Juan [2 ,4 ,5 ]
Gonzalez-Garcia, Juan [2 ,6 ,7 ]
Brochado-Kith, Oscar [1 ,2 ]
Fernandez-Rodriguez, Amanda [1 ,2 ]
Diez, Cristina [2 ,4 ,5 ]
Hontanon, Victor [2 ,6 ,7 ]
Perez-Latorre, Leire [2 ,4 ,5 ]
Mican, Rafael [2 ,6 ,7 ]
Barbas, Coral [3 ]
Resino, Salvador [1 ,2 ]
Jimenez-Sousa, Maria Angeles [1 ,2 ]
机构
[1] Inst Salud Carlos III ISCIII, Ctr Nacl Microbiol CNM, Unidad Infecc Viral & Inmunidad, Madrid, Spain
[2] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Infecciosas, Madrid, Spain
[3] Univ CEU San Pablo, Fac Farm, Dept Quim & Bioquim, Ctr Metab & Bioanal CEMBIO,Urbanizac Monteprincip, Madrid 28925, Spain
[4] Hosp Gen Univ Gregorio Maranon, Unidad Enfermedades Infecciosas VIH, Madrid, Spain
[5] Inst Invest Sanitaria Gregorio Maranon IiSGM, Madrid, Spain
[6] Hosp Univ La Paz, Serv Med Interna Unidad VIH, Madrid, Spain
[7] Inst Invest Sanitaria La Paz IdiPAZ, Madrid, Spain
关键词
Chronic hepatitis C; HIV; Cirrhosis; Metabolomics; DAAs therapy; HCV elimination; HUMAN-IMMUNODEFICIENCY-VIRUS; AMINO-ACID GRANULES; EVENT-FREE SURVIVAL; HEPATITIS-C; LIVER-DISEASE; HEPATOCELLULAR-CARCINOMA; PROGRESSION; SOFOSBUVIR; FIBROSIS;
D O I
10.1016/j.biopha.2022.112623
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: A better understanding of the evolution of cirrhosis after hepatitis C virus (HCV) clearance is essential since the reversal of liver injury may not happen. We aimed to assess the evolution of plasma metabolites after direct-acting antivirals (DAAs) therapy and their association with liver disease scores in HIV/HCV-coinfected patients with advanced HCV-related cirrhosis. Methods: We performed a prospective study in 49 cirrhotic patients who started DAAs therapy. Data and samples were collected at baseline and 36 weeks after SVR. Metabolomics analysis was carried out using gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry. Inflammation-related biomarkers were analyzed using ProcartaPlex Immunoassays. Results: At 36 weeks after SVR, patients experienced significant decrease in taurocholic acid, 2,3-butanediol, and LPC(18:0); while several phosphatidylcholines (LPC(16:1), LPC(18:1), LPC(20:4), and PC(16:0/9:0(CHO))/PC (16:0/9:0(COH)), 2-keto-n-caproic acid/2-keto-isocaproic acid and N-methyl alanine increased, compared to baseline. The plasma decrease in taurocholic acid was associated with a reduction in Child-Turcotte-Pugh (CTP) (AMR-3.39; q-value=0.006) and liver stiffness measurement (LSM) (AMR-1.06; q-value<0.001), the plasma increase in LPC(20:4) was related to a reduction in LSM (AMR-0.98; q-value=0.027), and the rise of plasma 2-keto-n-caproic acid/2-keto-isocaproic acid was associated with a reduction in CTP (AMR-0.35; q-value=0.004). Finally, plasma changes in taurocholic acid were directly associated with inflammation-related biomarkers, while changes in LPC(20:4) were inversely associated. Conclusions: Plasma metabolomic profile changed after HCV clearance with all oral-DAAs in HIV/HCV-coinfected with advanced HCV-related cirrhosis. Changes in plasma levels of LPC (20: 4), 2-keto-n-caproic acid/2-keto-isocaproic acid, and taurocholic acid were related to improvements in cirrhosis scores and inflammatory status of patients.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis
    Nicolás Merchante
    Francisco Téllez
    Antonio Rivero-Juárez
    Maria José Ríos-Villegas
    Dolores Merino
    Manuel Márquez-Solero
    Mohamed Omar
    Eva Recio
    Montserrat Pérez-Pérez
    Ángela Camacho
    Sara Macías-Dorado
    Juan Macías
    Sandra Lorenzo-Moncada
    Antonio Rivero
    Juan A. Pineda
    BMC Infectious Diseases, 15
  • [42] CCR5+T-Cells Homed to the Liver Exhibit Inflammatory and Profibrogenic Signatures in Chronic HIV/HCV-Coinfected Patients
    Shrivastava, Shikha
    Kottilil, Shyam
    Sherman, Kenneth E.
    Masur, Henry
    Tang, Lydia
    VIRUSES-BASEL, 2021, 13 (10):
  • [43] Evaluation of APRI score in liver disease following the introduction of antiretroviral therapy in HIV and HCV coinfected versus HIV monoinfected patients
    Antonello, Vicente Sperb
    Tovo, Cristiane Valle
    Kliemann, Dimas Alexandre
    Santos, Breno Riegel
    Zaltron, Vanice Ferrazza
    REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL, 2010, 43 (06) : 678 - 681
  • [44] Challenges Facing Providers Caring for HIV/HCV-Coinfected Patients
    Lekas, Helen-Maria
    Siegel, Karolynn
    Leider, Jason
    QUALITATIVE HEALTH RESEARCH, 2012, 22 (01) : 54 - 66
  • [45] The Risk of Cardiovascular Disease, Diabetes, Liver-Related Outcomes, and Death Over 10 Years in HIV/HCV-Coinfected Patients With and Without Steatosis
    Down, Carrie
    Mehta, Natasha
    Marks, Kristen
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2016, 32 (09) : 868 - 871
  • [46] Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C)
    Hernandez-Novoa, Beatriz
    Moreno, Ana
    Perez-Elias, Maria J.
    Quereda, Carmen
    Dronda, Fernando
    Casado, Jose L.
    Madrid-Elena, Nadia
    Aguilar, Monica
    Fumero, Emilio
    Molto, Jose
    Moreno, Santiago
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (02) : 471 - 475
  • [47] Similar recovery of liver function after response to all-oral HCV therapy in patients with cirrhosis with and without HIV coinfection
    Macias, Juan
    Granados, Rafael
    Tellez, Francisco
    Merino, Dolores
    Perez, Montserrat
    Morano, Luis E.
    Palacios, Rosario
    Paniagua, Maria
    Frias, Mario
    Merchante, Nicolas
    Pineda, Juan A.
    Merchante, Nicolas
    Mancebo, Maria
    Rivero, Antonio
    Rivero-Juarez, Antonio
    Marquez, Manuel
    Ojeda, Guillermo
    Santos, Jesus
    Romero, Josefa
    de los Santos, Ignacio
    Omar, Mohamed
    Amparo Gomez-Vidal, Ma
    Prado, Eva
    Piera, Guiomar
    Martinez, Rosa
    Toyas, Carla
    JOURNAL OF VIRAL HEPATITIS, 2019, 26 (01) : 16 - 24
  • [48] Sustained Long-Term Antiviral Maintenance Therapy in HCV/HIV-Coinfected Patients (SLAM-C)
    Sherman, Kenneth E.
    Andersen, Janet W.
    Butt, Adeel A.
    Umbleja, Triin
    Alston, Beverly
    Koziel, Margaret J.
    Peters, Marion G.
    Sulkowski, Mark
    Goodman, Zachary D.
    Chung, Raymond T.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 55 (05) : 597 - 605
  • [49] European Mitochondrial DNA Haplogroups and Metabolic Disorders in HIV/HCV-Coinfected Patients on Highly Active Antiretroviral Therapy
    Micheloud, Dariela
    Berenguer, Juan
    Guzman-Fulgencio, Maria
    Campos, Yolanda
    Garcia-Alvarez, Monica
    Catalan, Pilar
    Cosin, Jaime
    Miralles, Pilar
    Carlos Lopez, Juan
    Resino, Salvador
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2011, 58 (04) : 371 - 378
  • [50] Sustained Long-Term Decline in Anti-HCV Neutralizing Antibodies in HIV/HCV-Coinfected Patients Five Years after HCV Therapy: A Retrospective Study
    Sepulveda-Crespo, Daniel
    Volpi, Camilla
    Amigot-Sanchez, Rafael
    Yelamos, Maria Belen
    Diez, Cristina
    Gomez, Julian
    Hontanon, Victor
    Berenguer, Juan
    Gonzalez-Garcia, Juan
    Martin-Escolano, Ruben
    Resino, Salvador
    Martinez, Isidoro
    PHARMACEUTICALS, 2024, 17 (09)